Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log-in |  Register |  Search

Back to the forum  Query: 2018-05-27 23:39 UTC (UTC+2h)
 

Multiple dose study for MR product in EU [Regulatives / Guidelines]

posted by Samaya B - India, 2014-09-27 09:06  - Posting: # 13599
Views: 2,004

» "A multiple dose study is needed unless a single dose study has been performed with the highest strength which has demonstrated that the mean AUC(0-τ) after the first dose covers more than 90% of mean AUC(0-∞) for both test and reference, and consequently a low extent of accumulation is expected".
»
» Please elaborate or simplify the same for better understanding.

Dear Mahesh,

You can consider "first dose" as a "single dose" study.

For MR products in EMEA, first perform pivotal BE study under fasting state and evalaute the results. If AUC0-t>0.9*AUCinf, you need not to go ahead for steady state BE study. BE under steady state is required when drug accumulates in body. If AUC0-t> 0.9*AUCinf is achieved after signle dose administration, normally, there would not be accumulation.

You can refer following posts as well: #12612, #7062, #8296

Hope this info would be helpful.

Regards,
Samaya.


Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post! [Helmut]

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,295 posts in 3,890 threads, 1,165 registered users;
17 users online (0 registered, 17 guests).

To know that we know what we know,
and to know that we do not know what we do not know,
that is true knowledge.    Nicolaus Copernicus

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
XHTML/CSS RSS Feed